Jasper Therapeutics (NASDAQ:JSPR) Given Outperform Rating at Royal Bank of Canada

Royal Bank of Canada restated their outperform rating on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research note released on Monday,Benzinga reports. They currently have a $68.00 price target on the stock.

A number of other equities research analysts have also recently commented on the stock. BMO Capital Markets started coverage on shares of Jasper Therapeutics in a report on Friday, December 6th. They issued an “outperform” rating and a $63.00 price target on the stock. JMP Securities restated a “market outperform” rating and issued a $70.00 target price on shares of Jasper Therapeutics in a research note on Tuesday, October 15th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. Evercore ISI restated an “outperform” rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research note on Monday, August 26th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a report on Thursday, October 24th. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $73.38.

Jasper Therapeutics Stock Performance

NASDAQ JSPR opened at $21.71 on Monday. The company has a market capitalization of $325.67 million, a PE ratio of -4.58 and a beta of 2.18. Jasper Therapeutics has a 52-week low of $5.02 and a 52-week high of $31.01. The company has a 50-day simple moving average of $21.88 and a 200 day simple moving average of $20.66.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in JSPR. BNP Paribas Financial Markets boosted its position in shares of Jasper Therapeutics by 208.6% in the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock valued at $47,000 after acquiring an additional 1,698 shares during the period. American Century Companies Inc. lifted its stake in Jasper Therapeutics by 27.1% in the 2nd quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock worth $322,000 after purchasing an additional 3,032 shares in the last quarter. Wolff Wiese Magana LLC bought a new position in Jasper Therapeutics in the 3rd quarter valued at $59,000. Fernwood Investment Management LLC grew its position in shares of Jasper Therapeutics by 6.9% during the 3rd quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company’s stock valued at $995,000 after purchasing an additional 3,427 shares in the last quarter. Finally, MetLife Investment Management LLC increased its holdings in shares of Jasper Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock worth $129,000 after purchasing an additional 3,873 shares during the period. Hedge funds and other institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.